International Journal of Cardiology
Volume 136, Issue 2 , Pages 186-192 , 14 August 2009

Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis

  • Ana Ruigómez

      Affiliations

    • Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain
    • Corresponding Author InformationCorresponding author. Spanish Centre for Pharmacoepidemiological Research (CEIFE), Almirante 28, 2°, 28004 Madrid, Spain. Tel.: +34 91 531 1485; fax: +34 91 531 2871.
    • ,
  • Saga Johansson

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • Section of Preventive Cardiology, Gothenburg University, Sweden
    • ,
  • Mari-Ann Wallander

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • Department of Public Health and Caring Science, Uppsala University, Sweden
    • ,
  • Nils Edvardsson

      Affiliations

    • AstraZeneca R&D, Mölndal, Sweden
    • Sahlgrenska University Hospital, Gothenburg, Sweden.
    • ,
  • Luis Alberto García Rodríguez

      Affiliations

    • Spanish Centre for Pharmacoepidemiological Research (CEIFE), Madrid, Spain

Received 15 October 2007 ,Revised 1 February 2008 ,Accepted 25 April 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Disclosures: this study was funded by a research grant from AstraZeneca R&D Mölndal, Sweden. Dr Wallander, Dr Johansson and Dr Edvardsson are employees of AstraZeneca. Dr Ruigómez and Dr García Rodríguez work for CEIFE, which has received research grants from AstraZeneca. The corresponding author had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

PII: S0167-5273(08)00630-X

doi: 10.1016/j.ijcard.2008.04.050

International Journal of Cardiology
Volume 136, Issue 2 , Pages 186-192 , 14 August 2009

Article Tools

* Image Usage & Resolution